Press Release
CGBIO launches ‘MEDICLORE’, an anti-adhesion agent in Indonesia

▲MEDICLORE Product Picture

The AOFOG holds a launching event… full-scale entry into the Indonesian anti-adhesion market
Inhibits adhesion by changing from sol to gel by body temperature when applied to the body

 

CGBIO(CEO Hyun Seung Yu), a company specializing in bio-regenerative medicine, enters the Indonesian market with MEDICLORE, a fourth-generation sol-gel type anti-adhesion agent.

CGBIO announced on the 30th that it held a launching event for MEDICLORE on the 24-26th at the AOFOG(Asia and Oceania Federation of Obstetrics and Gynecology Congress) held in Bali, Indonesia, running a lunch symposium presentation and promotion booth.

MEDICLORE exists as the liquid form ‘sol’ at room temperature, and after applied to the body changes to a highly viscous ‘gel’ state by body temperature, acting as a physical barrier in the area expected to be adhered after surgery to prevent adhesion while the wound recovers. It can be used for various surgical operations such as spine, joint, mastectomy, obstetrics and gynecology, prostate resection, and digestive surgery.

The main components of MEDICLORE are Poloxamer and Chitosan. Poloxamer forms a physical barrier through a temperature-dependent change process to directly inhibit adhesion, and Chitosan helps tissues recover quickly without infection through antibacterial and hemostatic effects.

Meanwhile, a lunch symposium was held on the 25th under the theme of “Management of Pelvic Adhesions in Gynecology Surgery”. Dr. Ruswana Anwar from Hasan Sadikin Hospital hosted the event and Dr. Herbert Situmorang from Cipto Mangunkusumo Hospital gave a presentation with the theme of “Pelvic Adhesions-What&Why”. Dr. Syarief Taufik Hidayat from Dr. Kariadi Hospital then gave a lecture of the theme of “Prevention and Handling Pelvic Adhesion”.

The lecture introduced the cause of pelvic adhesion, the necessity of an anti-adhesion agent, and the advantages of applying MEDICLORE for pelvic adhesion, drawing attention from many medical staff.

CEO Hyun Seung Yu said, “MEDICLORE is a fourth-generation anti-adhesion agent with excellent anti-adhesion effects, and is the no.1 product in Korean anti-adhesion market. Now we will work with our local partner Kalbe Farma to carry out various marketing activities for the successful landing of MEDICLORE in Indonesia, beyond Korea.”

He added, “Starting with the launch of MEDICLORE in Indonesia, we will try to provide greater benefits to the medical staff and patients around the world, including Thailand, the Philippines, and Vietnam, where we are currently exporting.”